Plain-English translation of NCT06792214 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 4 — The treatment has already been approved. Researchers are tracking how it works in a large number of people over time.
The DEFEND trial is testing whether Paxlovid or Veklury (two antiviral medications) can help prevent serious heart problems, strokes, and blood clots that sometimes develop after COVID-19 infection. Researchers want to understand if treating COVID-19 early with these medications might protect your heart and blood vessels in the months following your hospital stay.
Some people develop serious heart and blood vessel problems months after their COVID-19 infection, even after recovering from the initial illness. This study is exploring whether treating the virus more aggressively early on might prevent these long-term complications.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the active medication or a placebo (inactive treatment) alongside your standard hospital care. You will take your assigned treatment by mouth twice daily or receive it through an IV once daily for 5 days. Researchers will then monitor you for up to one year after your hospital stay, tracking whether you develop any heart-related complications, strokes, blood clots, or other serious health events.
AI-generated summary from trial data · Jun 9, 2026 · Not medical advice
Canada